How GLP-1 Medications Work for Weight Loss

GLP-1 medications have generated more excitement in medicine than almost anything in the past decade. And for good reason — the clinical trial results are remarkable. But a lot of the coverage has been breathless and imprecise. Here's a clear, accurate explanation of how these drugs actually work.

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It's a hormone your body naturally produces in your gut — specifically in your small intestine — after you eat. It's part of a family of hormones called incretins.

When food enters your intestine, GLP-1 is released and does several things:

• Signals your pancreas to produce insulin (lowering blood sugar)
• Suppresses glucagon, which prevents your liver from dumping excess glucose
• Slows gastric emptying, meaning food moves more slowly from your stomach to your intestine
• Signals your brain — specifically the hypothalamus — that you're full

In people without obesity or diabetes, this system works well. The problem is that GLP-1 has a very short half-life — it's broken down within minutes. The body's natural GLP-1 signal doesn't last long enough to meaningfully suppress appetite over hours or days.

What GLP-1 Medications Do Differently

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) are synthetic molecules engineered to bind to the same receptors as natural GLP-1 — but resist the enzyme that normally breaks it down.

The result: the GLP-1 signal lasts for days rather than minutes.

This prolonged signaling drives the weight loss effect through several mechanisms:

Appetite suppression in the brain

The most important mechanism for weight loss isn't the stomach — it's the brain. GLP-1 receptors are present in the hypothalamus and other brain regions that regulate hunger, reward, and satiety. When a GLP-1 medication binds to these receptors, it meaningfully reduces appetite, decreases food cravings, and lowers the drive to eat for pleasure (sometimes called "food noise").

Many patients describe this as: "I can look at my favorite food and just... not feel compelled to eat it." That's the central GLP-1 effect. A [20-week randomized trial of semaglutide 2.4 mg](https://pubmed.ncbi.nlm.nih.gov/33269530/) found it reduced hunger, increased fullness and satiety, lowered ad libitum energy intake by about 35%, and produced fewer and weaker food cravings versus placebo — providing direct mechanistic evidence for the appetite and "food noise" effects patients describe (appetite/cravings were secondary endpoints; the trial's primary endpoint of gastric emptying showed no clear delay at week 20 once corrected for weight loss).

Slowed gastric emptying

GLP-1 slows how quickly your stomach empties. This means food stays in your stomach longer, extending the feeling of fullness after a meal. You feel satisfied sooner and stay full longer.

Blood sugar regulation

By stimulating insulin release in a glucose-dependent way (only when blood sugar is elevated) and suppressing glucagon, GLP-1 medications improve blood sugar control. This is why semaglutide was originally developed as a diabetes drug.

Importantly, this insulin-stimulating effect is glucose-dependent — meaning it only kicks in when blood sugar rises. This significantly reduces the risk of hypoglycemia (dangerously low blood sugar).

Why the Results Are So Significant

Clinical trials for semaglutide at 2.4mg/week (Wegovy) showed an average of 15% body weight reduction over 68 weeks — the [STEP 1 trial](https://pubmed.ncbi.nlm.nih.gov/33567185/) (Wilding et al., N Engl J Med 2021) reported a mean change of -14.9% in the semaglutide group versus -2.4% in the placebo group at week 68 in 1,961 adults with overweight or obesity without diabetes. Tirzepatide trials showed even higher numbers — up to 20-22% body weight reduction in some trials, including the [SURMOUNT-1 trial](https://pubmed.ncbi.nlm.nih.gov/35658024/) (Jastreboff et al., N Engl J Med 2022), which reported -20.9% mean weight loss at 72 weeks with the 15 mg dose. These are numbers that lifestyle interventions alone rarely achieve and maintain.

For context: previous weight loss medications typically produced 5-8% weight loss. The difference is meaningful — both in absolute terms and in the associated health benefits.

What These Medications Don't Do

It's important to be clear about what GLP-1 drugs don't do:

• They don't eliminate the need for healthy eating and activity
• They don't work the same for everyone — response varies
• They typically require ongoing use to maintain results; most people regain weight when they stop
• They have real side effects, most commonly nausea, vomiting, and GI discomfort, especially early on

Who Is a Candidate?

GLP-1 medications for weight loss are generally approved for:

• Adults with a BMI of 30 or higher, or
• Adults with a BMI of 27 or higher who have at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea)

A physician evaluates your full health history before prescribing, because these medications are not appropriate for everyone.

[Start your weight loss evaluation](/start) — talk to a real doctor about GLP-1 options.

---

Related Articles

• [How Long Does Semaglutide Take to Work?](/blog/how-long-does-semaglutide-take-to-work)
• [Semaglutide vs. Tirzepatide: Which Is Better?](/blog/semaglutide-vs-tirzepatide-comparison)
• [Semaglutide Side Effects Week by Week](/blog/semaglutide-side-effects-week-by-week)